Research peptides are not approved for human use in most countries including India. This page is for educational purposes only. Consult a physician before use.
What is AOD-9604?
AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide corresponding to amino acids 176–191 of the C-terminal region of human growth hormone (HGH), with a tyrosine at the N-terminus added for stability. This specific region of HGH is the portion responsible for lipolytic (fat-breaking) activity.
The rationale for isolating this fragment is elegant: full HGH stimulates growth and IGF-1 production throughout the body, including effects that increase insulin resistance and theoretical risk of cell proliferation. If only the fat-metabolizing activity could be isolated in a fragment, you would get the weight management benefit without the metabolic and safety concerns of full HGH.
AOD-9604 was developed by Metabolic Pharmaceuticals (an Australian company) specifically as an anti-obesity drug, and was the first peptide to complete Phase II clinical trials focused on fat loss.
Why No IGF-1 Stimulation Matters
Full human growth hormone works through two parallel mechanisms:
- Direct receptor binding: GH receptor activation → lipolysis, glucose effects, direct tissue effects
- IGF-1 induction: Liver produces IGF-1 in response to GH → anabolic effects, cell proliferation, insulin sensitization/resistance
AOD-9604 activates lipolysis through the beta-3 adrenergic receptor pathway, bypassing the GH receptor entirely. This means:
- No IGF-1 elevation — no theoretical cell proliferation concern
- No insulin resistance induction
- No growth promotion effects
- Metabolically cleaner fat-specific activity
Clinical Trial History
AOD-9604 progressed through Phase II clinical trials for obesity under Metabolic Pharmaceuticals:
- Multiple Phase II trials in the early 2000s tested oral and injectable AOD-9604 in overweight and obese adults
- Results were mixed — some trials showed modest but statistically significant reduction in body fat, particularly visceral and subcutaneous fat; others showed non-significant results
- The FDA GRAS (Generally Recognized As Safe) status was obtained for AOD-9604 — one of the few research peptides to clear this bar
- Phase III trials were not conducted for obesity — the effect size was deemed insufficient to justify the investment in a post-semaglutide competitive landscape
AOD-9604 should not be compared favorably to GLP-1 agonists for fat loss. Semaglutide (Wegovy) produces 15–17% body weight reduction. AOD-9604's Phase II results were modest and inconsistent — in the range of 1–2 kg over several months. Different league entirely.
Cartilage Research: A Different Direction
AOD-9604 has shown more consistent promise in a completely different area — cartilage and osteoarthritis:
- Studies by Metabolic Pharmaceuticals found AOD-9604 stimulates cartilage and bone regeneration in animal models
- A Phase II RCT for knee osteoarthritis showed significant improvements in pain and function vs placebo
- This may represent a more viable application than obesity treatment, given the consistent cartilage data and India's high burden of osteoarthritis
AOD-9604 vs GLP-1 Drugs
| Feature | AOD-9604 | Semaglutide (Wegovy) |
|---|---|---|
| Mechanism | Beta-3 adrenergic activation (cellular metabolic shift) | GLP-1 receptor agonism (CNS appetite suppression) |
| Average weight loss | Modest, inconsistent (1–3 kg in trials) | 15–17% body weight in Phase III trials |
| IGF-1 effect | None | None |
| FDA status | GRAS (safe), not approved as drug | FDA approved for obesity |
| Phase III trials | Not completed for obesity | Completed — highly effective |
| Additional benefits | Cartilage repair (Phase II) | Cardiovascular protection, T2DM |
Dosing (Circulating Protocols)
Common protocols used in research and biohacking communities — not validated clinical dosing:
- Dose: 300–500 mcg subcutaneously daily
- Timing: Before exercise or in the morning (fasted state may enhance lipolytic effect)
- Cycle: 8–12 weeks
- Reconstitution: Lyophilized powder with bacteriostatic water
Frequently Asked Questions
Does AOD-9604 cause weight loss?
AOD-9604 showed modest fat reduction in some Phase II trials but results were inconsistent. The effect size is substantially smaller than GLP-1 agonists like semaglutide. It may have some lipolytic activity, particularly for visceral fat, but is not a meaningful obesity treatment by current standards.
How does AOD-9604 differ from full HGH?
AOD-9604 is just the C-terminal fragment (amino acids 176–191) of HGH responsible for lipolytic activity. It does not stimulate IGF-1, does not cause insulin resistance, and does not have the growth-promoting effects of full HGH. This makes it safer metabolically but also limits its anabolic benefits.
What is AOD-9604's safety profile?
AOD-9604 obtained FDA GRAS (Generally Recognized as Safe) status from Phase II trials — making it one of the few research peptides with formal human safety validation. No IGF-1 elevation or insulin resistance was observed in trials. The safety profile was acceptable.
AOD-9604 vs semaglutide for fat loss — which is better?
This comparison is not close. Semaglutide (Ozempic/Wegovy) consistently produces 10–15% body weight reduction in clinical trials. AOD-9604's Phase II trials showed modest and inconsistent results. If the goal is meaningful fat loss, GLP-1 agonists have overwhelmingly stronger evidence.